William L. Macias

Myovant Sciences (United States) — United States

Medicine · Health Sciences

50h-index14.8kcitations125works4.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sepsis Diagnosis and Treatment(39), Rheumatoid Arthritis Research and Therapies(18), Dialysis and Renal Disease Management(16), Acute Kidney Injury Research(14), Chronic Lymphocytic Leukemia Research(14)

Publications124 total

Batoclimab Induces Very Rapid and Sustained Post-treatment Euthyroidism in Graves' Disease
Endocrine Abstracts·2026
Euthyroidism and Long-Term Remission of Graves’ Hyperthyroidism Following Treatment With an FcRn Blocker: A Case Report
Thyroid·2026
Efficacy and safety of the FCRN inhibitor, batoclimab, in graves' thyroidal and extrathyroidal disease: a proof-of-concept study
Endocrine Abstracts·2025
Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
BMJ Neurology Open·2024· 17 citedOpen Access
Subcutaneous batoclimab in generalized myasthenia gravis: Results from a Phase 2a trial with an open‐label extension
Annals of Clinical and Translational Neurology·2023· 16 citedOpen Access
Proof-of-concept and Randomized, Placebo-controlled Trials of an FcRn Inhibitor, Batoclimab, for Thyroid Eye Disease
The Journal of Clinical Endocrinology & Metabolism·2023· 57 citedOpen Access
EL ESTUDIO DE LA ORGANIZACIÓN SOLIDARIA EN COLOMBIA Y SU CONTEXTO DE DIVERSIDAD
Editora Artemis eBooks·2020Open Access
Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations
Arthritis Research & Therapy·2019· 273 citedOpen Access
MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis
The Journal of Rheumatology·2019· 8 citedOpen Access
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
The Journal of Rheumatology·2018· 252 citedOpen Access
Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study
Annals of the Rheumatic Diseases·2018· 81 citedOpen Access
Characterization and Changes of Lymphocyte Subsets in Baricitinib‐Treated Patients With Rheumatoid Arthritis
Arthritis & Rheumatology·2018· 37 citedOpen Access
JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
Journal of Clinical Investigation·2018· 497 citedOpen Access
Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies
Annals of the Rheumatic Diseases·2018· 53 citedOpen Access
Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis
Lara D. Veeken·2018· 59 citedOpen Access
JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial
Nephrology Dialysis Transplantation·2017· 267 citedOpen Access
Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients
Clinical Pharmacology & Therapeutics·2017· 124 cited
Dose/Exposure‐Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis
CPT Pharmacometrics & Systems Pharmacology·2017· 28 citedOpen Access
AB0281 Characterization of changes in lymphocyte subsets in baricitinib-treated patients with early, dmard naÏve, rheumatoid arthritis in a phase 3 study
Annals of the Rheumatic Diseases·2017· 2 citedOpen Access
Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: A 52-week, randomized, single-blind, extension study
Modern Rheumatology·2017· 37 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

Terence Rooney(10), Jonathan Janes(8), Mark D. Williams(8), Douglas Schlichting(8), Jean-François Dhainaut(6), Mark C. Genovese(6), Bruce A. Mueller(6), Peter C. Taylor(5), Scott D. Beattie(5), Jean‐Louis Vincent(5), Gordon R. Bernard(5), David R. Nelson(5), Stephen D. Wiviott(4), Elliott M. Antman(4), Stephanie de Bono(4), Howard Levy(4), David P. Sundin(4), William R. Clark(4), David S. Small(4), Antonio Artigas(3)